518 related articles for article (PubMed ID: 11368288)
1. Amifostine: an update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome.
Culy CR; Spencer CM
Drugs; 2001; 61(5):641-84. PubMed ID: 11368288
[TBL] [Abstract][Full Text] [Related]
2. The potential of amifostine: from cytoprotectant to therapeutic agent.
Santini V; Giles FJ
Haematologica; 1999 Nov; 84(11):1035-42. PubMed ID: 10553165
[TBL] [Abstract][Full Text] [Related]
3. A risk-benefit assessment of amifostine in cytoprotection.
Mabro M; Faivre S; Raymond E
Drug Saf; 1999 Nov; 21(5):367-87. PubMed ID: 10554052
[TBL] [Abstract][Full Text] [Related]
4. Chemoprotective and radioprotective effects of amifostine: an update of clinical trials.
Capizzi RL; Oster W
Int J Hematol; 2000 Dec; 72(4):425-35. PubMed ID: 11197208
[TBL] [Abstract][Full Text] [Related]
5. Amifostine: chemotherapeutic and radiotherapeutic protective effects.
Santini V
Expert Opin Pharmacother; 2001 Mar; 2(3):479-89. PubMed ID: 11336600
[TBL] [Abstract][Full Text] [Related]
6. Amifostine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as a radioprotector and cytotoxic chemoprotector.
Spencer CM; Goa KL
Drugs; 1995 Dec; 50(6):1001-31. PubMed ID: 8612469
[TBL] [Abstract][Full Text] [Related]
7. Economic analysis of amifostine as adjunctive support for patients with advanced head and neck cancer: preliminary results from a randomized phase II clinical trial from Germany.
Bennett CL; Lane D; Stinson T; Glatzel M; Buntzel J
Cancer Invest; 2001; 19(2):107-13. PubMed ID: 11296615
[TBL] [Abstract][Full Text] [Related]
8. Amifostine in simultaneous radiochemotherapy of advanced head and neck cancer.
Büntzel J; Glatzel M; Kuttner K; Weinaug R; Fröhlich D
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):4-13. PubMed ID: 11917277
[TBL] [Abstract][Full Text] [Related]
9. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer.
Brizel DM; Wasserman TH; Henke M; Strnad V; Rudat V; Monnier A; Eschwege F; Zhang J; Russell L; Oster W; Sauer R
J Clin Oncol; 2000 Oct; 18(19):3339-45. PubMed ID: 11013273
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
Anné PR
Semin Oncol; 2002 Dec; 29(6 Suppl 19):80-3. PubMed ID: 12577250
[TBL] [Abstract][Full Text] [Related]
11. Amifostine in clinical oncology: current use and future applications.
Koukourakis MI
Anticancer Drugs; 2002 Mar; 13(3):181-209. PubMed ID: 11984063
[TBL] [Abstract][Full Text] [Related]
12. Selective cytoprotection with amifostine in concurrent radiochemotherapy for head and neck cancer.
Büntzel J; Küttner K; Fröhlich D; Glatzel M
Ann Oncol; 1998 May; 9(5):505-9. PubMed ID: 9653491
[TBL] [Abstract][Full Text] [Related]
13. Amifostine for protection from antineoplastic drug toxicity.
Foster-Nora JA; Siden R
Am J Health Syst Pharm; 1997 Apr; 54(7):787-800. PubMed ID: 9099346
[TBL] [Abstract][Full Text] [Related]
14. Amifostine (WR-2721), a cytoprotective agent during high-dose cyclophosphamide treatment of non-Hodgkin's lymphomas: a phase II study.
De Souza CA; Santini G; Marino G; Nati S; Congiu AM; Vigorito AC; Damasio E
Braz J Med Biol Res; 2000 Jul; 33(7):791-8. PubMed ID: 10881054
[TBL] [Abstract][Full Text] [Related]
15. Protection of normal tissue from the cytotoxic effects of chemotherapy and radiation by amifostine: clinical experiences.
Capizzi RL; Oster W
Eur J Cancer; 1995; 31A Suppl 1():S8-13. PubMed ID: 7577096
[TBL] [Abstract][Full Text] [Related]
16. Amifostine: the first selective-target and broad-spectrum radioprotector.
Kouvaris JR; Kouloulias VE; Vlahos LJ
Oncologist; 2007 Jun; 12(6):738-47. PubMed ID: 17602063
[TBL] [Abstract][Full Text] [Related]
17. Randomized double-blind trial of amifostine versus placebo for radiation-induced xerostomia in patients with head and neck cancer.
Lee MG; Freeman AR; Roos DE; Milner AD; Borg MF
J Med Imaging Radiat Oncol; 2019 Feb; 63(1):142-150. PubMed ID: 30461207
[TBL] [Abstract][Full Text] [Related]
18. Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients.
Rades D; Fehlauer F; Bajrovic A; Mahlmann B; Richter E; Alberti W
Radiother Oncol; 2004 Mar; 70(3):261-4. PubMed ID: 15064010
[TBL] [Abstract][Full Text] [Related]
19. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer.
Kemp G; Rose P; Lurain J; Berman M; Manetta A; Roullet B; Homesley H; Belpomme D; Glick J
J Clin Oncol; 1996 Jul; 14(7):2101-12. PubMed ID: 8683243
[TBL] [Abstract][Full Text] [Related]
20. [Side effects of postoperative radiochemotherapy with amifostine versus radiochemotherapy alone in head and neck tumors. Preliminary results of a prospective randomized trial].
Vacha P; Marx M; Engel A; Richter E; Feyerabend T
Strahlenther Onkol; 1999 Nov; 175 Suppl 4():18-22. PubMed ID: 10584135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]